Bannerbild German Brest Group

The Lancet - Breast Cancer Series 2016

08.12.2016

The introduction of targeted therapies has profoundly changed the course of some subtypes of breast cancer—but many challenges remain. The Lancet’s 2016 Series on breast cancer discusses the most recent advances in the three most common breast cancer subtypes. The first pair of papers focus on the treatment of advanced oestrogen-receptor-positive and HER2-positive breast cancers, while the third describes how an improved understanding of molecular alterations in the heterogeneous and hard-to-treat triple-negative breast cancer may lead to more refined and more effective therapy. http://www.thelancet.com/series/breast-cancer-2016

News

  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd